Breast cancer occurs in the breast ducts and lobe of the breast and ranks the first with 25.2% of female cancers worldwide. The incidence of breast cancer has increased about 4 times. In compared to 20 years ago, it is the second largest female cancer in Korea due to obesity, reduced breastfeeding, and westernization. Additionally, every year 20,000 women have been diagnosed with breast cancer, accounting for 70% in their 40s and 50s. (Annual reports in National Cancer Center, 2018)
The VEUS system to monitor breast cancer for proper treatment
1. Needs
Breast cancer is usually screened by the mammography and breast ultrasound methods. When abnormalities are found, magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET) are further performed. These methods are all expensive. Most of the korean women have to perform several tests when screening for dense breast. If blood testing is used for diagnosis of breast cancer, it can save cost with rapid and accurate results.
2. The VEUS system for diagnosis of breat cancer
Conventional treatments for breat cancer are different depending on whether the HR (ER, PR) protein is overexpressed (approximately 70% patients) or HER 2 protein is overexpressed (approximately 15% patients). For HR-positive patients, Letrozole, a chemotherapeutic agent is used and for HER 2 protein-positive patients, therapeutic antibodies are used.
For breast cancer patients who are positive for HR (ER, PR) proteins, therapeutic antibodies against new proteins have been developed. These proteins can be used as important markers for treatment efficancy and recurrence.
We are currently developing the VEUS system to monitor concentratons of new markers for breast cancer.